

AMENDMENTS TO THE CLAIMS

1-65. (canceled).

66. (currently amended) A vector for expressing a single-stranded oligonucleotide in a bacterial or fungal cell, comprising:

- a promoter;
- a set of inverted tandem repeats located 3' to the promoter;
- a cloning site flanked by the set of inverted tandem repeats or located 3' to the set of inverted tandem repeats;
- a primer binding site (PBS) for a reverse transcriptase located 3' to the cloning site having a sequence that is recognized by tRNA_{Val} in the presence of the reverse transcriptase; and
- an expression termination sequence located 3' to the PBS.

67. (previously presented) The cloning vector according to claim 66, further comprising a gene coding for the reverse transcriptase.

68. (previously presented) The vector according to claim 67, wherein the reverse transcriptase is a mouse Maloney virus reverse transcriptase.

69. (previously presented) The vector according to claim 66, further comprising an origin of replication.

70. (canceled).

71. (previously presented) The vector according to claim 66, wherein the primer binding site (PBS) has a sequence: TGGTGCCTCCGAG [SEQ ID NO: 3].

72. (previously presented) The vector according to claim 66, wherein the promoter is a bacterial promoter.

73. (previously presented) The vector according to claim 66, wherein the promoter is inducible.

74. (previously presented) The vector according to claim 73, wherein the promoter is inducible by tetracycline or a tetracycline analog.

75. (previously presented) The vector according to claim 66, wherein the vector is pssXG.

76. (previously presented) The vector according to claim 66, further comprising an oligonucleotide insert inserted at the cloning site.

77. (previously presented) A library for expressing single-stranded oligodeoxynucleotides, comprising a plurality of vectors according to claim 76, wherein the oligonucleotide inserts in the plurality of vectors have different nucleotide sequences.

78. (previously presented) The library according to claim 77, wherein the oligonucleotide inserts have sequences of: 5'-N₁-GGCTAGCTACAAACGA-N₂ [SEQ ID NO: 7], wherein N₁ and N₂ each

represent a nucleotide sequence having a random sequence and a length from 3 to 25 nucleotides long.

79. (currently amended) A cell having a vector or library according to claim 66 ~~therein~~.
80. (withdrawn) A method for screening an oligodeoxynucleotide that modulates a cell function using the library of claim 77, wherein the promoter in the vector is inducible, the method comprising: transfecting the library into host cells; growing the transfected host cells on replica plates, one of the replica plates including an agent for inducing expression of single-stranded oligodeoxynucleotides from the oligonucleotide inserts in the vectors in the transfected host cells; comparing the induced and non-induced replica plates to identify a host cell having a different phenotype; and sequencing the oligonucleotide insert in the vector from the host cell having a different phenotype.
81. (previously presented) The vector of claim 76, wherein the oligonucleotide insert is determined to have a sequence of:

5'-CTTCAACAGTTTGATGACCTTGCTGACCATAATTGC-
GATATCGTGGGGAGTGAGAG-3' [SEQ ID NO: 14],
5'-CTCATACTCT-3' [SEQ ID NO: 33],
5'-GTTCGAAGGCTAGCTACAAACGATCATCCAG-3' [SEQ ID NO: 6], or
5'-CCTGCTTAGGCTAGCTACAAACGATGGTCACC-3' [SEQ ID NO: 8].
82. (withdrawn) An isolated or intracellularly expressed oligonucleotide comprising a sequence of:

5'-CTTCAACAGTTTGATGACCTTGCTGACCATAATTGC-
GATATCGTGGGGAGTGAGAG-3' [SEQ ID NO: 14],
5'-CTCATACTCT-3' [SEQ ID NO: 33],
5'-GTTCGAAGGCTAGCTACAAACGATCATCCAG-3' [SEQ ID NO: 6],
5'-CCTGCTTAGGCTAGCTACAAACGATGGTCACC-3' [SEQ ID NO: 8],
or a sequence homologous to SEQ ID NO: 6, 8, 14, or 33.
83. (currently amended) A cell or cell culture having one or more having the oligonucleotide or library vectors according to claim 77 84 transfected therein.
84. (withdrawn) A method for inhibiting bacterial, fungal or other microbial growth or reducing toxin activity, comprising contacting bacteria, fungi or other microorganism with the oligonucleotide or vector of claim 81.
85. (withdrawn) A method for inhibiting bacterial, fungal or other microbial growth or reducing toxin activity, comprising contacting bacteria, fungi or other microorganism with the vector of claim 76.

86. (withdrawn) The method of claim 84, wherein the bacteria, fungi or other microorganism is a sepsis causative agent.
87. (withdrawn) The use of oligonucleotide or vector of claim 76 in the manufacture of a medicament for the treatment of sepsis.
88. (withdrawn) A method for reducing or blocking sepsis-related toxin activity or sepsis-induced immune responses, comprising contacting a bodily fluid with the oligonucleotide or vector of claim 76.